Thus, potent activation of STING signaling and innate immune responses by the tumor cell-targeted STINGa ADCs have the potential to drive efficacy in cancers, including those resistant to T cell-mediated elimination, in addition to stimulating anti-tumor NK cell or T cell activity and inducing long-term immune memory, particularly in combination with CPI treatments. Here, STING1 is linked to cancer.